Clinical Trials · NCT06644040
A Study of TeriQ Patch in Healthy Adult Female Participants
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- QuadMedicine
- Enrollment
- 24
- Start date
- Oct 2024
- Locations
- 2 sites, Australia
- Primary endpoint
- To evaluate the pharmacokinetic (PK) endpoints of teriparatide following a single dose administration of TeriQ Patch- Maximum plasma concentration (Cmax)